Ambeed.cn

首页 / / / / Diclofenac Sodium Salt/双氯芬酸钠

Diclofenac Sodium Salt/双氯芬酸钠 {[allProObj[0].p_purity_real_show]}

货号:A105695 同义名: Diclofenac Sodium; GP 45840

Diclofenac Sodium Salt是一种非选择性环氧化酶(COX)抑制剂。常用作非类固醇抗炎药(NSAID),用于缓解疼痛和减少炎症。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Diclofenac Sodium Salt/双氯芬酸钠 化学结构 CAS号:15307-79-6
Diclofenac Sodium Salt/双氯芬酸钠 化学结构
CAS号:15307-79-6
Diclofenac Sodium Salt/双氯芬酸钠 3D分子结构
CAS号:15307-79-6
Diclofenac Sodium Salt/双氯芬酸钠 化学结构 CAS号:15307-79-6
Diclofenac Sodium Salt/双氯芬酸钠 3D分子结构 CAS号:15307-79-6
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Diclofenac Sodium Salt/双氯芬酸钠 纯度/质量文件 产品仅供科研

货号:A105695 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 COX COX-1 COX-2 其他靶点 纯度
Piroxicam 98%
Salicylic acid 98%
Phenacetin 98%
Etodolac 99%
Flunixin meglumine 98%
Ibuprofen L-lysine 98%
Nabumetone 98%
Acemetacin 98%
Diflunisal 98%
Pranoprofen 98%
Ampiroxicam 98%
Meloxicam 98%
Sulindac 98%
Ketoprofen 98%
Mefenamic Acid 95%
Bromfenac sodium 98%
Oxaprozin 99%
Aspirin 99%
Nepafenac 98%
Zaltoprofen 99%
Salicin 98%
Suprofen 99%+
Xanthohumol 99%
Parecoxib 98%
Tolfenamic Acid +++

COX-2, IC50: 0.2 μM

98%
Etoricoxib 99%
Niflumic Acid 98%
Valdecoxib ++++

COX-2, IC50: 5 nM

99+%
Ibuprofen +

COX-1, IC50: 13 μM

+

COX-2, IC50: 370 μM

98%
Indomethacin ++

COX1, IC50: 0.28 μM

+

COX-2, IC50: 14 μM

97%
Lornoxicam ++++

COX-1, IC50: 5 nM

++++

COX-2, IC50: 8 nM

98%
Meclofenamic acid sodium ++++

COX-1, IC50: 40 nM

+++

COX-2, IC50: 50 nM

99%
Asaraldehyde 98%
Naproxen +

COX-1, IC50: 8.7 μM

+

COX-2, IC50: 5.2 μM

98%
Diclofenac Sodium Salt +++

COX-1, IC50: 60 nM

+++

COX-2, IC50: 200 nM

98%
NS-398 ++

COX-2, IC50: 3.8 μM

95%
Amfenac Sodium Hydrate ++

COX-1, IC50: 250 nM

+++

COX-2, IC50: 150 nM

98%+
Nimesulide +

COX-2, IC50: 26 μM

98%
Lumiracoxib ++

COX-1, Ki: 3 μM

+++

COX-2, Ki: 60 nM

98%
Rutaecarpine 95%
Celecoxib ++++

COX-2, IC50: 40 nM

98%
Carprofen ++++

canine COX2, IC50: 30 nM

98%
Ketorolac ++

COX-1 (human), IC50: 1.23 μM

++

COX-2 (human), IC50: 3.50 μM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Diclofenac Sodium Salt/双氯芬酸钠 生物活性

靶点
  • COX-2

    COX-2, IC50:200 nM

  • COX-1

    COX-1, IC50:60 nM

描述 Diclofenac Sodium (GP 45840) is a potent, nonselective anti-inflammatory agent that functions as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells[1]. Diclofenac Sodium triggers apoptosis in neural stem cells (NSCs) by activating the caspase cascade[3].

Diclofenac Sodium Salt/双氯芬酸钠 细胞实验

Cell Line
Concentration Treated Time Description References
MRSE ATCC 35984 125 µg mL−1 24 hours Inhibits MRSE growth Adv Sci (Weinh). 2021 May 3;8(13):2100681.
MSSA ATCC 25923 125 µg mL−1 24 hours Inhibits MSSA growth Adv Sci (Weinh). 2021 May 3;8(13):2100681.
Mouse adult tail-tip fibroblasts (TTFs) 10 μM 1 week Diclofenac significantly enhanced cardiac reprogramming efficiency in adult TTFs by about 3 fold Nat Commun. 2019 Feb 20;10(1):674.
Mouse postnatal tail-tip fibroblasts (TTFs) 10 μM 1 week Diclofenac significantly enhanced cardiac reprogramming efficiency in postnatal TTFs by 3-4 fold Nat Commun. 2019 Feb 20;10(1):674.
Mouse embryonic fibroblasts (MEFs) 10 μM 1 week Diclofenac did not substantially promote cardiac reprogramming in MEFs Nat Commun. 2019 Feb 20;10(1):674.
Mouse primary hepatocytes 300 µM 24 hours To evaluate the effect of diclofenac on lipid accumulation in mouse primary hepatocytes, results showed that diclofenac significantly increased neutral lipid accumulation and triglyceride levels. Theranostics. 2022 Feb 21;12(5):2351-2369.
HepG2 cells 300 µM 24 hours To evaluate the effect of diclofenac on lipid accumulation in hepatocytes, results showed that diclofenac significantly increased neutral lipid accumulation. Theranostics. 2022 Feb 21;12(5):2351-2369.
MRSA ATCC 43300 125 µg mL−1 24 hours Inhibits MRSA growth and does not easily induce drug-resistant mutations Adv Sci (Weinh). 2021 May 3;8(13):2100681.
Intestinal microsomes 100 μmol/L 30 minutes To evaluate the metabolic rate of diclofenac in intestinal microsomes, results showed that the formation rates of 4'-OH-DCF and 5-OH-DCF were reduced by 58% and 64%, respectively, in DSS-induced colitis mice. Acta Pharm Sin B. 2020 Jan;10(1):123-135.
Hepatic microsomes 100 μmol/L 30 minutes To evaluate the metabolic rate of diclofenac in hepatic microsomes, results showed that the formation rates of 4'-OH-DCF (CYP2C metabolite) and 5-OH-DCF (CYP3A metabolite) were reduced by 23% and 27%, respectively, in DSS-induced colitis mice. Acta Pharm Sin B. 2020 Jan;10(1):123-135.
Fibroblast-like synoviocytes (FLS) 147.1 μmol/L (DC) and 73.6 μmol/L (LND) 24 hours To verify the synergistic inhibitory effect of diclofenac (DC) and lonidamine (LND) on the survival, proliferation, and activation of FLS. Results showed that the combination treatment significantly reduced FLS viability and induced higher apoptosis rates (31.6%). Acta Pharm Sin B. 2025 Jan;15(1):542-556.
Fadu cells 10ug/g  every other day To investigate the effect of diclofenac on LAMP2A expression, results showed that diclofenac significantly decreased LAMP2A expression levels. Theranostics. 2025 Feb 18;15(7):3207-3222.

Diclofenac Sodium Salt/双氯芬酸钠 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Rats Carrageenan-induced rat paw edema model Oral 10 mg/kg Single dose Evaluation of anti-inflammatory activity, diclofenac sodium showed 81.62% inhibition. Acta Pharm Sin B. 2017 Mar;7(2):230-240
C57BL/6 mice Osteoarthritis pain model Oral 10 mg/kg Daily for 4 weeks To evaluate the analgesic effect of diclofenac on mechanical joint loading-induced osteoarthritis pain. Results showed that diclofenac significantly alleviated mechanical hypersensitivity and improved weight distribution after 2 weeks of treatment. Arthritis Rheumatol. 2019 Jul;71(7):1078-1088
C57BL/6 mice Hepatic steatosis model Intraperitoneal injection 100 mg/kg Every 12 hours for 24 hours To evaluate the effect of diclofenac on hepatic lipid accumulation in mice, results showed that diclofenac significantly increased hepatic lipid accumulation and triglyceride levels. Theranostics. 2022 Feb 21;12(5):2351-2369.
C57BL/6 mice Head and neck squamous cell carcinoma model Intraperitoneal injection 10 μg/g Every other day for 10 days To investigate the effect of diclofenac combined with PD-1 monoclonal antibody treatment, results showed that the combination treatment significantly inhibited tumor growth and enhanced CD8+ T cell infiltration. Theranostics. 2025 Feb 18;15(7):3207-3222.
CD1 ICR mice Skin and soft tissue infection model Subcutaneous injection 80 mg/kg Every 24 hours for 7 days Combination with oxacillin significantly alleviates MRSA infection Adv Sci (Weinh). 2021 May 3;8(13):2100681.
Nude mice 11q-deleted neuroblastoma xenograft model Drinking water 250 mg/L Nine consecutive days To assess the effect of COX inhibition on tumor growth in an 11q-deleted neuroblastoma model, results showed diclofenac treatment significantly reduced tumor growth and PGE2 levels. Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8070-5

Diclofenac Sodium Salt/双氯芬酸钠 参考文献

[1]Riendeau D, et al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17.

[2]Labib MB, et al. Design, synthesis of novel isoindoline hybrids as COX-2 inhibitors: Anti-inflammatory, analgesic activities and docking study. Bioorg Chem. 2018 Oct;80:70-80.

Diclofenac Sodium Salt/双氯芬酸钠 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.14mL

0.63mL

0.31mL

15.72mL

3.14mL

1.57mL

31.43mL

6.29mL

3.14mL

Diclofenac Sodium Salt/双氯芬酸钠 技术信息

CAS号15307-79-6
分子式C14H10Cl2NNaO2
分子量 318.13
SMILES Code O=C([O-])CC1=CC=CC=C1NC2=C(Cl)C=CC=C2Cl.[Na+]
MDL No. MFCD00082251
别名 Diclofenac Sodium; GP 45840; Diclofenac(sodium salt); Diclofenac(Sodium)
运输蓝冰
InChI Key KPHWPUGNDIVLNH-UHFFFAOYSA-M
Pubchem ID 5018304
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, room temperature

溶解方案

H2O: 10 mg/mL(31.43 mM),配合低频超声,并水浴加热至45℃助溶

配制的工作液建议现用现配,短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。